A carregar...
Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential
The field of cannabinoid (CB) drug research is experiencing a challenge as the CB(1) antagonist Rimonabant, launched in 2006 as an anorectic/anti-obesity drug, was withdrawn from the European market due to the complications of suicide and depression as side effects. There is interest in developing C...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3501202/ https://ncbi.nlm.nih.gov/pubmed/22300098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/fmc.11.179 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|